According to filings with the U.S. Securities and Exchange Commission, Deverra Therapeutics is raising $2,388,889.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Michael Yurkowsky played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Deverra Therapeutics
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.

To learn more about Deverra Therapeutics, visit http://www.deverratx.com/

Contact:
Michael Yurkowsky, Chief Executive Officer
214-478-8208

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.